Revvity Inc
XMUN:PKN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Revvity Inc
XMUN:PKN
|
US |
|
F
|
Franco-Nevada Corp
XBER:3FO
|
CA |
Revvity Inc
Revvity makes tools and tests used in laboratories that study biology and diagnose disease. Its products include laboratory instruments, reagents, assay kits, software, and related services that help customers measure biological signals, run genetic and biochemical tests, and analyze results. The company serves drug developers, biotech and academic research labs, and clinical and public health laboratories. The company makes money in a few main ways: it sells instruments and software systems upfront, and it also sells the consumable chemicals, test kits, and service contracts that customers keep buying after the equipment is installed. That gives Revvity a mix of one-time sales and recurring revenue tied to the ongoing use of its platforms. In diagnostics, its products help labs detect and monitor disease; in research, they help scientists discover and develop new medicines. What makes Revvity’s business model distinct is that it sits in the middle of the lab workflow. It does not just sell standalone equipment; it sells the tools, tests, and support that labs use repeatedly to generate data and make decisions. That makes the company an important supplier to both healthcare testing and life sciences research, where customers care about accuracy, reliability, and easy-to-run workflows.
Revvity makes tools and tests used in laboratories that study biology and diagnose disease. Its products include laboratory instruments, reagents, assay kits, software, and related services that help customers measure biological signals, run genetic and biochemical tests, and analyze results. The company serves drug developers, biotech and academic research labs, and clinical and public health laboratories.
The company makes money in a few main ways: it sells instruments and software systems upfront, and it also sells the consumable chemicals, test kits, and service contracts that customers keep buying after the equipment is installed. That gives Revvity a mix of one-time sales and recurring revenue tied to the ongoing use of its platforms. In diagnostics, its products help labs detect and monitor disease; in research, they help scientists discover and develop new medicines.
What makes Revvity’s business model distinct is that it sits in the middle of the lab workflow. It does not just sell standalone equipment; it sells the tools, tests, and support that labs use repeatedly to generate data and make decisions. That makes the company an important supplier to both healthcare testing and life sciences research, where customers care about accuracy, reliability, and easy-to-run workflows.
Beat and raise: Revvity reported a strong Q1 with $711 million of revenue, 3% organic growth, 23.6% adjusted operating margin, and $1.06 of adjusted EPS, all above expectations.
China divestiture: Management announced plans to divest the immunodiagnostics business in China, saying it is a lower-growth, lower-margin business facing persistent policy pressure and capital demands.
Guidance reset: Full-year 2026 guidance now excludes that China business and calls for 3% to 4% organic growth, 28.4% adjusted operating margin, and $5.20 to $5.30 of adjusted EPS.
End markets: Pharma/biotech and academic spending improved modestly in Q1, while reproductive health was strong and diagnostics outside China performed in line with expectations.
Software momentum: Revvity said customer interest in its software and AI offerings remains high, with strong SaaS/ARR growth and several launches planned for 2026.
Margin path: Management expects margins to step up through the year as cost actions take hold, with further benefit in 2027 once the current efficiency program is annualized.
